Document:

Agreement and Plan of Merger - Amendment No. 1

 Exhibit 10.1 

Execution Copy 

AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER 

This AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER (this “Amendment”) is entered into as of
            , 2010 by and among FirstEnergy Corp., an Ohio corporation (“Parent”), Element Merger Sub, Inc., a Maryland corporation and a direct wholly-owned subsidiary of
Parent (“Merger Sub”), and Allegheny Energy, Inc., a Maryland corporation (the “Company”). 

W I T N E S S E T H: 

WHEREAS, Parent, Merger Sub, and the Company (collectively, the “Parties”) entered into an Agreement and Plan of Merger
dated as of February 10, 2010 (the “Agreement”); 
 WHEREAS, Section 8.12 of the Agreement permits
amendments to the Agreement if in writing and signed by each of the Parties; and 
 WHEREAS, the Parties desire to amend the
Agreement as provided in this Amendment. 
 AGREEMENT: 

NOW, THEREFORE, in consideration of the foregoing and the representations, warranties, covenants and agreements contained herein, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows: 

Section 1. Defined Terms. Capitalized terms used in this Amendment without separate definition shall have the respective
meanings assigned to them in the Agreement. 
 Section 2. Amendment to Section 4.3. Section 4.3(a) of the
Agreement is hereby amended by amending and restating the third sentence of such section as follows: 
 “The Board of
Directors of Parent has unanimously resolved to recommend (the “Parent Recommendation”) that Parent’s shareholders authorize and approve the issuance of shares of Parent Common Stock in connection with the Merger (the
“Stock Issuance”) and the other Transactions and adopt an amendment to Parent’s articles of incorporation providing for an increase in the authorized capital stock of Parent to 495,000,000 shares (the “Charter
Amendment”), and such resolutions have not been subsequently rescinded, modified or withdrawn in any way.” 

Section 3. Amendment to Section 4.17. Section 4.17(a) of the Agreement is hereby amended and restated in its
entirety to read as follows: 
 “The affirmative vote of holders of a majority of the outstanding shares of Parent
Common Stock is the only vote of the holders of any class or series of Parent capital stock necessary to (i) authorize and approve the Stock Issuance and the other 

 
Transactions and (ii) adopt the Charter Amendment (collectively, the “Parent Shareholder Approval”), and no other vote of the holders of any class or series of Parent
capital stock is necessary to authorize or approve this Agreement or the Transactions.” 
 Section 4. Amendment to
Section 5.6. Section 5.6(b) of the Agreement is hereby amended and restated in its entirety to read as follows: 

“Each of the Company and Parent shall, as promptly as practicable after the Form S-4 is declared effective under the Securities Act,
take all action necessary in accordance with applicable Laws and the Company Organizational Documents, in the case of the Company, and the Parent Organizational Documents, in the case of Parent, to duly give notice of, convene and hold a meeting of
its stockholder or shareholders, respectively, to be held as promptly as practicable to consider, in the case of Parent, the authorization and approval of the Stock Issuance and the other Transactions and the adoption of the Charter Amendment (the
“Parent Shareholders’ Meeting”) and, in the case of the Company, the adoption of this Agreement and the approval of the Transactions including the Merger (the “Company Stockholders’ Meeting”). Except in
the case of a Company Change of Recommendation in accordance with the terms of this Agreement, the Company will, through its Board of Directors, recommend that its stockholders adopt this Agreement and will use reasonable best efforts to solicit
from its stockholders proxies in favor of the adoption of this Agreement and to take all other action necessary or advisable to secure the vote or consent of its stockholders required by the rules of the NYSE or applicable Laws to obtain such
approvals. Except in the case of a Parent Change of Recommendation in accordance with the terms of this Agreement, Parent will, through its Board of Directors, recommend that its shareholders authorize and approve the Stock Issuance and the other
Transactions and adopt the Charter Amendment, and will use reasonable best efforts to solicit from its shareholders proxies in favor of the Stock Issuance and the other Transactions and the Charter Amendment and to take all other action necessary or
advisable to secure the vote or consent of its shareholders required by the rules of the NYSE or applicable Laws to obtain such approvals.” 

Section 5. Effect of Amendment. The Parties agree that except as otherwise set forth herein, all terms, conditions and
provisions of the Agreement shall remain in full force and effect. In the event of any inconsistency or conflict between the Agreement and this Amendment, the terms, conditions and provisions of this Amendment shall govern and control. 

Section 6. Dissenters’ Rights. Each of the Parties hereby acknowledges that in connection with the Transactions Parent
intends to offer the holders of Parent Common Stock dissenters’ rights as described in the applicable provisions of the Ohio General Corporation Law. 

Section 7. Entire Agreement. From and after the execution of this Amendment by the Parties, any reference to the Agreement
shall be deemed to be a reference to the Agreement as amended hereby. 
 Section 8. Governing Law. This Amendment
shall be governed by and construed in accordance with the Laws of the State of New York, without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the
application of the Laws of any jurisdiction other than the State of New York. 
  

 2 

 Section 9. Counterparts. This Amendment may be executed in two or more
counterparts, each of which shall constitute an original, and all of which taken together shall constitute one instrument. Any signature page delivered by a facsimile machine shall be binding to the same extent as an original signature page.

 Section 10. Headings. The section headings contained in this Amendment are inserted for convenience only and
shall not affect in any way the meaning or interpretation of this Amendment. 
 [SIGNATURE PAGE FOLLOWS] 

 

 3 

 IN WITNESS WHEREOF, the Parties have caused this Amendment to be duly executed and delivered
as of the date first above written. 
  

					
	 FIRSTENERGY CORP.

			
		 	By:	 	 /s/ Anthony J. Alexander

		 	Name:	 	Anthony J. Alexander
		 	Title:	 	President and Chief Executive Officer
	
	 ELEMENT MERGER SUB, INC.

		
	By:	 	 /s/ Mark T. Clark

		 	Name:	 	Mark T. Clark
		 	Title:	 	Executive Vice President and Chief Financial Officer
	
	 ALLEGHENY ENERGY, INC.

		
	By:	 	 /s/ Paul J. Evanson

		 	Name:	 	Paul J. Evanson
		 	Title:	 	Chairman, President & Chief Executive Officer

  

 4First Amendment, dated June 3, 2010.

 Exhibit 10.1 

FIRST AMENDMENT TO 

MYRIAD PHARMACEUTICALS, INC. 

Executive Severance and Change in Control Agreement 

This First Amendment to Myriad Pharmaceuticals, Inc. Executive Severance and Change in Control Agreement (this “Amendment”) is
made and entered into this 3rd day of June, 2010, by and between Barbara Berry (the “Executive”) and Myriad Pharmaceuticals, Inc. (the “Company”). 

W I T N E S S E T H 

WHEREAS, the Executive and the Company entered into an Executive Severance and Change in Control Agreement dated February 1,
2010 (the “Agreement”); and 
 WHEREAS, the Executive and the Company desire to amend the Agreement to change
the severance benefits Executive will receive upon termination of Executive’s employment from the Company under certain circumstances. 

NOW, THEREFORE, in consideration of the promises and mutual covenants and agreements contained herein and other good and valuable
consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows: 
 1. Section 4.2(a) of
the Agreement is amended in its entirety to read as follows: 
 (a) Termination Without Cause or for Good
Reason. If the Executive’s employment with the Company is terminated by the Company (other than for Cause, Disability or death) or by the Executive for Good Reason, then the Executive shall be entitled to the following benefits: 

(i) the Company shall pay to the Executive the following amounts: 

(1) the Executive’s base salary through the Date of Termination; 

(2) any accrued vacation pay to the extent not previously paid; 

(3) $204,883, in a lump sum, in cash, within 30 days after the Date of Termination; 

(ii) if the Executive is covered under the Company’s group health plan immediately prior to the Date of Termination,
then if the Executive timely elects to continue such coverage under COBRA, the Company will pay the premium for the Executive’s COBRA coverage until the earlier of (A) six months from the Date of Termination and (B) the date the
Executive becomes covered under another group health plan; and 

 (iii) any equity award(s) issued to the Executive shall be governed by and
subject to the terms and conditions of the applicable award agreement. 
 2. The parties hereby agree that the Agreement will
continue to be in full force and effect as modified by the terms of this Amendment. 
 IN WITNESS WHEREOF, the
parties have executed this Amendment as of the day and year first written above. 
  

					
	MYRIAD PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Adrian N. Hobden

		 	Name:	 	Adrian N. Hobden, Ph.D.
		 	Title:	 	President and CEO
	
	 /s/ Barbara Berry

	Barbara Berry

  

 2Waiver and Acknowledgement

 EXHIBIT 10.10 

WAIVER AND ACKNOWLEDGEMENT 

May 27, 2010 
 WHEREAS: 

A. Reference is made to the following agreements dated effective February 24, 2009 between University Health Network (“UHN”) and Med
BioGene Inc. (“MBI”): 
  

	 	(i)	Additional Exclusive License Agreement; 

  

	 	(ii)	Additional Sponsored Research Agreement (“Additional Research Agreement”); 

 

	 	(iii)	Amended and Restated Exclusive License Agreement; and 

  

	 	(iv)	Amended and Restated Sponsored Research Agreement (the “Amended Research Agreement”) 

(collectively, the “Agreements”). 

B. UHN and MBI have agreed, among other things, to undertake certain research (the “Research”) relating to prognostic mRNA expression-based
signatures to be used in the clinical management of lung cancers in accordance with the procedures, specifications and timelines (the “Timelines”) described in each of the Additional Research Agreement and the Amended Research Agreement
and as further described in detail in Schedule A to each of the aforementioned agreements. 
 C. Certain of the Research is, as of the date
hereof, in progress and, as such, has not been completed within the timelines described in Schedule A to each of the Additional Research Agreement and the Amended Research Agreement. 

D. UHN and MBI wish to waive the requirement that the Research be completed in accordance with the Timelines. 

NOW THEREFORE, in consideration of terms and conditions outlined below, the receipt and sufficiency of which is hereby acknowledged by UHN and MBI, such
parties agree as follows: 
 1. UHN and MBI hereby waive the requirement that the Research be completed in accordance with the Timelines and
further acknowledge and agree that each party will in good faith use commercially reasonable efforts to complete the Research as soon as reasonably practicable, subject to the suspension of the Research by MBI pursuant to section 9.6 of each of the
Additional Research Agreement and the Amended Research Agreement. 
 2. All other terms and conditions of the Agreements remain in full force
and effect and shall be read and interpreted in light of the application of this Waiver and Acknowledgement. 
  

													
	UNIVERSITY HEALTH NETWORK	 	MED BIOGENE INC.
					
	Per:	 	/s/ BRIAN H. BARBER	 		 	Per:	 	/s/ ERINN B. BROSHKO
		 	Name:	 	Brian H. Barber, Ph.D.	 		 		 	Name:	 	Erinn B. Broshko 
		 	Title:	 	Director, Technology Development and Commercialization	 		 		 	Title:	 	Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00174-of-00352.parquet"}]]